Abstract
Current standard treatments for cancer are associated with major dose-limiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and antiinflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however rational targeting of intervention strategies to critical mechanisms will lead to further progress.
Keywords: Mucosal injury, mucositis, chemotherapy, radiotherapy, inflammation, apoptosis, growth factor, intestine, oral
Recent Patents on Anti-Cancer Drug Discovery
Title: Prevention and Treatment of Regimen-Related Mucosal Toxicity
Volume: 3 Issue: 2
Author(s): Joanne M. Bowen
Affiliation:
Keywords: Mucosal injury, mucositis, chemotherapy, radiotherapy, inflammation, apoptosis, growth factor, intestine, oral
Abstract: Current standard treatments for cancer are associated with major dose-limiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and antiinflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however rational targeting of intervention strategies to critical mechanisms will lead to further progress.
Export Options
About this article
Cite this article as:
Bowen M. Joanne, Prevention and Treatment of Regimen-Related Mucosal Toxicity, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638802
DOI https://dx.doi.org/10.2174/157489208784638802 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Patent Selections
Recent Patents on Anti-Cancer Drug Discovery 3D-QSAR Studies of HDAC6 Inhibitors Using Docking-Based Alignment
Letters in Drug Design & Discovery Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
Cardiovascular & Hematological Agents in Medicinal Chemistry Sphingosine Analogs and Protein Phosphatase 2A as a Molecular Targeted Cancer Therapy: A Mini Systematic Review
Clinical Cancer Drugs Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) Inhibitors of Vascular Endothelial Growth Factor in Cancer
Cardiovascular & Hematological Agents in Medicinal Chemistry Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Current Drug Safety Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Reviews on Recent Clinical Trials Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Current Medicinal Chemistry Clinical Pharmacogenomics of Thiopurine S-methyltransferase
Current Clinical Pharmacology Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients
Current Clinical Pharmacology Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy The Clinical Characteristics and Survival Profiles of Wilms Tumor in the United Arab Emirates: A Single-center Retrospective Analysis
New Emirates Medical Journal Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy